Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too.

Autor:	Perehudoff K; Law Centre for Health and Life, Faculty of Law, University of Amsterdam, Amsterdam, The Netherlands katrina.perehudoff@gmail.com.; WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.; Medicines Law & Policy, Amsterdam, The Netherlands., 't Hoen E; Medicines Law & Policy, Amsterdam, The Netherlands.; Transboundary Legal Studies, University of Groningen Faculty of Law, Groningen, The Netherlands., Boulet P; Medicines Law & Policy, Contamine sur Arve, France.
Jazyk:	angličtina
Zdroj:	BMJ global health [BMJ Glob Health] 2021 Apr; Vol. 6 (4).
DOI:	10.1136/bmjgh-2021-005518
Abstrakt:	Competing Interests: Competing interests: This work was in part supported by a grant from Unitaid to the COVID-19 Innovations for all consortium. KP is an advisory board member of the Pharmaceutical Accountability Foundation and Chair of the HAI Europe Association Board. PB is a part-time employee of the Drugs for Neglected Diseases Initiative. EtH isRapporteur of the Global Health Law Committee of the International Law Association; Member of the WHO Expert Advisory Panel on Drug Policies and Management; Member of the Advisory Board of Universities Allied for Essential Medicines (UAEM); Member of the Editorial Board of the Journal of Public Health Policy; President of the Knowledge Ecology International - Europe Association; Member of the Scientific Advisory Board of Utrecht Centre for Affordable Biotherapeutics; Member of the advisory board of the Pharmaceutical Accountability Foundation.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu